6-amino-1-hydroxyhexane-1,1-diphosphonate and Bone Loss, Perimenopausal

6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with Bone Loss, Perimenopausal in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	4 (57.14)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adami, S; Bertoldo, F; Costi, D; Di Munno, O; Filipponi, P; Fiore, CE; Frediani, B; Gatti, D; Marcocci, C; Palummeri, E; Rossini, M; Sartori, L	1
Adami, S; Braga, V; Dhangana, R; Fracassi, E; Gatti, D; Kalpakcioglu, B; Rossini, M; Viapiana, O	1
Adami, S; Fracassi, E; Gatti, D; Idolazzi, L; Rossini, M; Viapiana, O	1
Adami, S; Battaglia, E; Braga, V; Colapietro, F; Gatti, D; Prizzi, R; Righetti, D; Rossini, M	1
Adami, S; Crepaldi, G; Filipponi, P; Sartori, L	1
Laversuch, CV; Robins, SP; Tobias, JH; Wilson, N	1
Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G	1

Reviews

1 review(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Bone Loss, Perimenopausal

Article	Year
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging clinical and experimental research, 2003, Volume: 15, Issue:4 Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid	2003

Trials

4 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Bone Loss, Perimenopausal

Article	Year
Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcified tissue international, 2008, Volume: 83, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Diphosphonates; Double-Blind Method; Female; Humans; Injections, Intramuscular; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Vitamin D	2008
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone, 2012, Volume: 50, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Genetic Markers; Humans; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome	2012
Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone, 2003, Volume: 33, Issue:3 Topics: Aged; Bone Density; Diphosphonates; Female; Femur Neck; Humans; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pilot Projects	2003
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:3 Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diphosphonates; Female; Humans; Infusions, Intravenous; Isoenzymes; Osteoporosis, Postmenopausal; Pamidronate; Structure-Activity Relationship; Triglycerides	2000

Other Studies

2 other study(ies) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Bone Loss, Perimenopausal

Article	Year
Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism. Calcified tissue international, 2011, Volume: 89, Issue:1 Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Cholecalciferol; Collagen Type I; Diphosphonates; Female; Femur Neck; Humans; Hyperparathyroidism, Primary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Time	2011
Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. Calcified tissue international, 1996, Volume: 59, Issue:5 Topics: Administration, Oral; Amino Acids; Chromatography, High Pressure Liquid; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause	1996

Article

Year

Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.

Calcified tissue international, 2011, Volume: 89, Issue:1

Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Cholecalciferol; Collagen Type I; Diphosphonates; Female; Femur Neck; Humans; Hyperparathyroidism, Primary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Time

2011

Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women.

Calcified tissue international, 1996, Volume: 59, Issue:5

Topics: Administration, Oral; Amino Acids; Chromatography, High Pressure Liquid; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause

1996